Alimera Sciences plans to raise $100m in a public offering of securities including common stock, preferred stock, debt securities, warrants and units.

The biopharmaceutical company plans to use the funds for general corporate purposes.

ThromboGenics NV plans to raise €10m ($11.82m) through a private placement of shares.

The placement was subscribed to by Novartis.

Biopharmaceutical company AbbVie has signed an agreement with biotechnology company Alector to develop medicines targeting Alzheimer’s disease and other neurodegenerative disorders.

“ThromboGenics NV plans to raise €10m ($11.82m) through a private placement of shares.”

Alector will carry out exploratory research, while AbbVie will have the option to conduct development and commercialisation activities under the agreement.

The deal will help the two companies to develop innovative therapies for Alzheimer’s disease. Both companies involved are based in the US.

South Korean pharmaceutical company Choa Pharmaceutical has raised KRW12bn ($10.59m) through a public offering of private convertible bonds.

The bonds are due on 24 April 2022.